Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis.
Yusuke GotoSatoki TanakaMasafumi MaruoSho SugawaraKazuto ChibaKanetaka MiyazakiAtsushi InoueTomohiko IchikawaMaki NagataPublished in: IJU case reports (2022)
Pembrolizumab may be a treatment option for plasmacytoid variant urothelial carcinoma following genomic analysis.